tag:blogger.com,1999:blog-5574479.post7467624434857379364..comments2024-03-28T16:45:51.051+00:00Comments on The IPKat: AIPPI Congress Report 4: Should Europe embrace a patent linkage system? Verónica RodrÃguez Arguijohttp://www.blogger.com/profile/05763207846940036921noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-5574479.post-43164319523639326662014-09-18T09:30:49.815+01:002014-09-18T09:30:49.815+01:00Orange Book listings are compulsory now?Orange Book listings are compulsory now?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-5574479.post-42659953337908457992014-09-18T08:54:45.304+01:002014-09-18T08:54:45.304+01:00David is asking too much. There is no damage to E...David is asking too much. There is no damage to European Pharma by late knowledge of a generic's approval plans. Once approval is obtained, the fact is public knowledge and the patentee can then plan for the effects of a pre-patent expiry launch, should it happen. David can also benefit from the public disclosure of clinical trial information that provided a useful alert to generic activity.<br /><br />What is missing is knowledge of all that pre-approval infringement activity, such that it cannot be blocked. However, such activity is now almost completely protected by changes to national laws in response to the EU Bolar Directive, now more sensibly implemented in the UK.Anonymousnoreply@blogger.com